Caribou Biosciences News

Truist Adjusts Price Target on Caribou Biosciences to $19 From $21, Maintains Buy Rating

Caribou Biosciences (CRBU) has an average buy rating and a price target range of $10 to $30, according to analysts polled by Capital IQ. Price: 3.6000, Change: +0.10, Percent Change: +2.86

MT NewswiresMay 9 17:23

Analysts Are Bullish on These Healthcare Stocks: Bio-Rad Laboratories (BIO), Caribou Biosciences (CRBU)

TipRanksMay 8 18:40

Caribou Biosciences | 10-Q: Quarterly report

Futu NewsMay 8 04:21 · Announcements

Press Release: Caribou Biosciences Reports First Quarter 2024 Financial Results and Provides Business Update

Caribou Biosciences Reports First Quarter 2024 Financial Results and Provides Business Update -- Advancing CB-010 ANTLER Phase 1 trial in 2L LBCL; initial dose expansion data to be presented at the 2

Dow JonesMay 8 04:05

Caribou Biosciences Reports First Quarter 2024 Financial Results And Provides Business Update

-- Advancing CB-010 ANTLER Phase 1 trial in 2L LBCL; initial dose expansion data to be presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting -- -- Expanding into autoimmun

Caribou BiosciencesMay 7 12:00

Caribou Biosciences to Participate in Upcoming Investor Conferences

BERKELEY, Calif., May 01, 2024 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced the company's

Caribou BiosciencesMay 1 12:00

Lacklustre Performance Is Driving Caribou Biosciences, Inc.'s (NASDAQ:CRBU) 27% Price Drop

Caribou Biosciences, Inc. (NASDAQ:CRBU) shareholders that were waiting for something to happen have been dealt a blow with a 27% share price drop in the last month. The recent drop has obliterated

Simply Wall StApr 25 18:51

Caribou Biosciences to Present Initial Dose Expansion Data From CB-010 ANTLER Phase 1 Trial in R/r B-NHL at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

BERKELEY, Calif., April 24, 2024 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced two abstract

Caribou BiosciencesApr 24 12:00

Caribou Biosciences Announces Oral Presentation on In Vivo Cas12a ChRDNA Genome Editing at the 27th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT)

BERKELEY, Calif., April 15, 2024 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced an abstract

Caribou BiosciencesApr 15 12:00

Buy Rating Affirmed: Caribou Biosciences' Promising Trials and Strategic Market Positioning

TipRanksApr 8 15:25

Sector Update: Health Care Stocks Lean Higher Pre-Bell Friday

Health care stocks were leaning higher pre-bell Friday, with the Health Care Select Sector SPDR Fund (XLV) up 0.5% and the iShares Biotechnology ETF (IBB) flat recently. Nutex Health (NUTX) shares sli

MT NewswiresApr 5 20:57

Kura Sushi Posts Upbeat Sales, Joins Caribou Biosciences, Krispy Kreme And Other Big Stocks Moving Higher In Friday's Pre-Market Session

U.S. stock futures were higher this morning, with the Dow futures gaining by around 100 points on Friday. Shares of Kura Sushi USA, Inc. (NASDAQ:KRUS) climbed 6% to $110.11 in pre-market trading foll

BenzingaApr 5 20:01

We're Hopeful That Caribou Biosciences (NASDAQ:CRBU) Will Use Its Cash Wisely

We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining exploration companies often lose money for years before finding success with a new tr

Simply Wall StApr 5 18:09

Analysts Offer Insights on Healthcare Companies: 3SBio (OtherTRSBF), UnitedHealth (UNH) and Caribou Biosciences (CRBU)

TipRanksApr 5 17:40

Analysts Are Bullish on Top Healthcare Stocks: Paragon 28 (FNA), Caribou Biosciences (CRBU)

TipRanksApr 5 17:00

Caribou Biosciences Advances With FDA Clearance and New Trials

TipRanksApr 5 04:24

Caribou Biosciences Expands Clinical Development Of CB-010 With FDA Clearance Of IND In Lupus

-- FDA has cleared Caribou's IND application for CB-010 in lupus nephritis and extrarenal lupus; GALLOP Phase 1 clinical trial expected to initiate by YE 2024 ---- Driven by encouraging initial safety

BenzingaApr 5 04:01

Biotech Roundtable: Who Will Bring the Next CRISPR Drug to Market?

Seeking AlphaApr 2 23:36

With 65% Institutional Ownership, Caribou Biosciences, Inc. (NASDAQ:CRBU) Is a Favorite Amongst the Big Guns

Yahoo FinanceApr 1 18:18

Poseida Therapeutics Appoints Syed Rizvi as Chief Medical Officer

Poseida Therapeutics (PSTX) late Monday said it appointed Syed Rizvi as new chief medical officer, starting April 1. Rizvi previously was the chief medical officer at Caribou Biosciences (CRBU).

MT NewswiresMar 26 05:04